



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>G01N 33/68, 33/573, C12P 21/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 90/10234</b>  <b>(43) International Publication Date:</b> 7 September 1990 (07.09.90)
<b>(21) International Application Number:</b> PCT/NL90/00023 <b>(22) International Filing Date:</b> 2 March 1990 (02.03.90)  <b>(30) Priority data:</b> 8900529 3 March 1989 (03.03.89) NL  <b>(71) Applicant (for all designated States except US):</b> EURO-DI-AGNOSTICS B.V. [NL/NL]; Wilmersdorf 24, P.O. Box 2820, NL-7303 CG Apeldoorn (NL). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only) :</b> RIJKSEN, Gerrit [NL/NL]; Wilhelminalaan 48, NL-3732 GL De Bilt (NL).  <b>(74) Agents:</b> DE BRUIJN, Leendert, C. et al.; Nederlandsch Octrooibureau, Scheveningsweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), SU, US.  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD AND KIT FOR DETERMINING TYROSINE-PHOSPHORYLATING AND DEPHOSPHORYLATING ACTIVITIES  <b>(57) Abstract</b>  A safe and sensitive method is provided for determining the tyrosine-phosphorylating or phosphotyrosine-dephosphorylating activity of a material, such as a human tissue sample, by reacting the sample with a polypeptide which contains (phospho)tyrosine residues and assaying the phosphorylated polypeptide by using an antibody to a polypeptide containing phosphotyrosine. The method can conveniently be performed using a diagnosis kit containing the polypeptide and the antibody. The method and the kit are useful for example for diagnosing tumours.		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic			SN	Senegal
CG	Congo	KR	Republic of Korea	SU	Soviet Union
CH	Switzerland	LI	Liechtenstein	TD	Chad
CM	Cameroon	LK	Sri Lanka	TG	Togo
DE	Germany, Federal Republic of	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

Method and kit for determining tyrosine-phosphorylating and dephosphorylating activities

The invention relates to a method for determining the tyrosine-phosphorylating or phosphotyrosine-dephosphorylating activity of a material to be investigated, such as an enzyme, by bringing the material into contact with a polypeptide containing tyrosine or phosphotyrosine respectively and a phosphate source or phosphate acceptor respectively and then assaying the phosphorylated polypeptide.

The determination of the tyrosine-phosphorylating or phosphotyrosine-dephosphorylating activity of material, in particular of biological material, is of great importance for diagnostic and prognostic purposes and, in addition, for research purposes. Thus, it is known that the phosphorylation of tyrosine is an important response mechanism to a number of biological processes such as the action of growth factors and oncogenes [Y. Yarden, Ann. Rev. Biochem. 57, 443-478 (1988); T. Hunter and J.A. Cooper in The Enzymes (edited by P.D. Boyer and E.G. Krebs), vol. XVII, pages 191-246, Acad. Press, Orlando, Fl. (1986)]. In breast cancer cells and also in other solid tumours, for example, the expression of oncogenes and growth factor receptors appears to result in a considerably increased tyrosine kinase activity, while in benign tumours, a less markedly increased activity is observed [H. Hennipman et al., Cancer Research, 49, 516-521 (1989)]. In the case of leukaemia reduced tyrosine phosphatase activity, i.e. a reduced phosphotyrosine dephosphorylation, is reported [D.A. Frank and A.C. Sartorelli, Cancer Res. 48, 52-58 (1988)]. In experimental systems it has also been shown that the addition of a specific tyrosine phosphatase inhibitor can give rise to a malign degeneration of cells [J.K. Klarlund, Cell 41, 707-717 (1985)].

To detect deviations in the cell growth and to determine the nature thereof, there is therefore a need for reliable and efficient methods for determining the tyrosine kinase activity or tyrosine phosphatase activity

The determination of the tyrosine kinase activity of breast tissue fractions by reacting the sample with a tyrosine-containing polypeptide and adenosine triphosphate labelled with radioactive phosphorus ( $^{32}\text{P}$ -ATP), after which the radioactive label incorporated in the polypeptide is measured, is known [A. Hennipman et al., Cancer Research, 49, 516-521 (1989)].

This method has the disadvantages which are always associated with a radioactive assay, viz. that the latter is cumbersome, requires safety precautions and cannot easily be carried out in large series. In addition, the use of radioactively labelled ATP has the further drawback that the ATP concentration in the determination medium may not be optimally chosen. Furthermore, an appreciable background signal is found, which is formed by the phosphorylation of other substrates present in the sample and irrelevant to the determination such as serine residues in proteins, and this results in a variable and sometimes inadequate limit of detection.

A method has now been found which does not have the disadvantages and drawbacks mentioned. This method can be carried out simply and without safety risks, it shows considerably less noise and background signals and thus needs little if any corresponding correction, and it has one and the same sensitivity and activity as, or better sensitivity and activity than, the known method.

The method for determining the tyrosine-phosphorylating or phosphotyrosine-dephosphorylating activity according to the preamble of this description is characterized in that the phosphorylated polypeptide is determined by using an antibody to polypeptide containing phosphotyrosine.

The antibodies against the polypeptide containing phosphotyrosine to be used in the method according to the invention may be polyclonal or monoclonal. Monoclonal and polyclonal phosphotyrosine antibodies have been described (see J.Y.J. Wang, Anal. Biochem. 172, 1-7 (1988) for a review article). The use of polyclonal antibodies has, as is known, the drawback of a low specificity and reproducibility. It is possible, however, to purify polyclonal phosphotyrosine antibodies, for example with the aid of chromatography.

graphy on a tyramine column, so that a specific antibody is obtained which approaches the properties of a monoclonal antibody in its operation. The antibody to be used is preferably monospecific. Monoclonal antibodies, for example propagated in mice, against phosphotyrosine residues in proteins have been described, for example 1G2 [Huhn et al., Proc. Natl. Acad. Sci. USA, 84, 4408-4412 (1987)], and such antibodies are obtainable commercially. At least five different types of immunogens have hitherto been used to induce monoclonal or polyclonal antibodies. Three of these types are analogues of phosphotyrosine coupled to carrier proteins, viz. p-azobenzyl phosphonate, bromoacetyl-O-phosphotyramine and phosphotyrosine itself. A fourth type of immunogen is composed of an artificial polypeptide containing phosphotyrosine and the fifth type is formed by naturally occurring proteins phosphorylated to tyrosine residues. The resulting antibodies are purified by, for example, immunoaffinity chromatography on immobilized phosphotyramine and are in all cases comparable as regards activity and specificity [J.Y.J. Wang, Anal. Biochem. 172, 1-7 (1988)].

The method for carrying out an immune reaction such as that between a protein containing phosphotyrosine and an antibody is known per se [J.Y.J. Wang, Anal. Biochem. 172, 1-7 (1988)]. The immune complex can be determined for example when the antibody is provided with a label such as a radioactive isotope (RIA), for example  $^{125}\text{I}$ , an enzyme (ELISA), for example horseradish peroxidase, a luminescent substance, a gold particle, biotin and the like. Another preferred method for detecting the immune complex is to provide the immunogen, i.e. the polypeptide containing tyrosine residues, with a label such as mentioned above, preferably an enzyme, instead of labelling the antibody. On the other hand, the immune complex can be determined with the aid of a second antibody against the first antibody. In the case where the first antibody is a mouse antiphosphotyrosine, such a second antibody may be, for example, an anti-mouse antibody produced in goats. Said second antibody is then preferably provided with a similar label.

As already stated, all the known labelling substances, such as enzyme labels, biotin, protein A with radioactive label, etc.

are in principle suitable as a label. It has been found that an antibody labelled with gold can advantageously be used in the method according to the invention because the detection thereof has a high sensitivity. A further increase in the sensitivity can be achieved by using enhancement of the signal with silver. The use of immunogold determinations and of the silver enhancement have been described by M. Moeremans et al., J. Immunol. Meth. 74, 353-360 (1984). Suitable gold-labelled antibodies are obtainable commercially, as are the silver reagents suitable for enhancement. The (silver)gold signal can be quantified by means of densitometry.

The method according to the invention can advantageously be used to determine the phosphorylating activity of tyrosine kinases, in particular within the framework of research and of the diagnosis of deviations in the cell growth, for example in tumours. In particular, this relates to determination of the activity of protein tyrosine kinases (PTK), i.e. enzymes which catalyse the phosphorylation of tyrosine units in protein substrates.

To phosphorylate tyrosine, a phosphate source, usually adenosine triphosphate (ATP) or guanosine triphosphate (GTP), is necessary. These phosphates, and in particular ATP, are also preferably used in the method according to the invention. The quantity and the concentration of ATP can be adapted to the practical requirements and may be much higher (for example 1 mM) than is achievable in the known determination with  $^{32}\text{P}$ -ATP.

The substrate for the phosphorylation reaction may be any polypeptide which contains tyrosine units and against which an antibody can be induced in phosphorylated form. This may be a natural or a synthetic polypeptide. The polypeptide also preferably contains amino acid residues other than tyrosine, for example glutamic acid, aspartic acid, alanine etc. It has been found that a polypeptide which has a random amino acid sequence and, in addition to tyrosine residues, also contains glutamic acid residues is readily phosphorylated and subsequently complexed (recognized) by an antibody. A readily usable polypeptide is, for example, a poly-GluNa/Tyr (4:1) (PGT) with a random structure.

The method according to the invention can also be used to

determine the dephosphorylating activity of tyrosine phosphatases, which activity can also be related to the occurrence of irregularities in the cell growth, for example in the case of leukaemia. The phosphate acceptor for the dephosphorylation of phosphotyrosine may, for example, be adenosine diphosphate (ADP) or guanosine diphosphate (GDP), but also water or other substances normally present in the determination medium. In keeping with the situation in the case of the phosphorylation, the substrate for the phosphatase reaction may be any polypeptide containing phosphotyrosine against which an antibody can be induced. For this purpose, a polypeptide which contains tyrosine usable for the kinase determination and of which at least some of the tyrosine residues are phosphorylated can be used, for example a synthetic polypeptide containing glutamic acid and phosphotyrosine.

The kinase or phosphatase determination can be carried out in a standard medium and under conditions which are standard for such assays. The phosphorylation reaction can be started by adding ATP to the mixture of sample, substrate and medium constituents. The reaction can be terminated by adding inhibitors such as ethylenediaminetetraacetic acid (EDTA) and/or ethyleneglycol bis(2-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA).

The phosphorylated polypeptide can then be attached to a solid carrier such as a membrane and can be brought into contact with the antibody, after which the immune complex is determined qualitatively or quantitatively. Instead, the polypeptide substrate can be attached to a solid carrier before the enzyme reaction is carried out, after which the further method is followed as described above. The mixture containing the phosphorylated polypeptide can also be brought into contact with an immobilized antibody and then be treated with a second antibody and be assayed. As mentioned before, it is also possible to label the polypeptide instead of the antibody, and to allow it to react with the immobilized antibody.

To carry out the method according to the invention, use can also be made of a polypeptide incorporating an additional antigen sequence. Another anchorage possibility for the immune complex is then obtained by using an additional antibody against said

additional antigen.

Prior to the determination of the sample to be investigated, a calibration line can be plotted of results obtained with enzymes having known activity or of a standard of phosphotyrosine-containing polypeptide of which the phosphotyrosine content is known.

The invention also relates to combinations of reagents ("kits") which are suitable for use in the method described above. The kit according to the invention contains at least one tyrosine-containing polypeptide or a phosphotyrosine-containing polypeptide and a protein containing a phosphotyrosine antibody. Said antibody is preferably monospecific and is, for example, monoclonal mouse antiphosphotyrosine. The antibody may be labelled, for example with a gold label. The kit may also contain a second antibody against the first antibody and possibly further agents for measuring the immune complex, such as silver as enhancer of the gold label and the like.

Furthermore, the kit may advantageously contain a buffered medium in which the determination can be carried out and also an inhibitor for the (de)phosphorylation reaction. In addition, the kit may contain a carrier for immobilizing polypeptide, for example a polyvinylidene fluoride membrane.

The kit is preferably suitable for determining kinase activity and then contains a tyrosine-containing polypeptide and possibly also a phosphate donor such as ATP. The kit may also be directed at the determination of phosphatase activity and then comprises a phosphotyrosine-containing polypeptide.

Preferably, the kit also contains an instruction for carrying out the method described above.

#### EXAMPLE I

##### Materials:

Polyvinylidene difluoride (PVDF) transfer membranes (Immobilon) were purchased from Millipore (Bedford, MA, USA); bovine serum albumin (BSA) and polyglutamate-tyrosine (PGT) having a mean molecular weight of 28,500 were obtained from Sigma (St.



Louis, MO, USA). [ $\gamma$ - $^{32}$ P]ATP (10-40 Ci/mmol) originated from New England Nuclear (Berkeley, CA, USA) and unlabelled ATP from Boehringer (Mannheim, FRG). The reagents for the immunogold staining method with silver enhancement originated from Janssen (Beerse, Belgium). Monoclonal antibodies against phosphotyrosine residues (monoclonal 1G2) originated from Oncogene Science (Manhasset, NY, USA). All the other reagents were of analytical purity.

Sources of protein tyrosine kinase (PTK) activity:

Cytosolic extracts of normal human breast tissue, benign breast tumours and malignant breast carcinomas were used as a source of PTK activity. Breast tissue samples from patients with juvenile hypertrophy were obtained while carrying out a reduction mammoplasty. Upon histological examination, these tissues did not exhibit any abnormality and were therefore regarded as normal breast tissue. Biopsies obtained after surgery were immediately brought to  $-80^{\circ}$  C and stored until used. Cytosol extracts were prepared by homogenizing a tumour sample in 10 mM Tris/HCl, pH 7.4, containing 0.25 M sucrose, 1 mM  $\text{MgCl}_2$ , 1 mM EDTA, 1 mM diisopropyl fluorophosphate, 1 mM phenylmethanesulfonyl fluoride, 1 mM dithiothreitol and 0.5 mg/ml aprotinin. Debris and nuclei were removed by centrifugation at 800 g for 10 min. at  $4^{\circ}$  C. The cytosol was isolated by ultracentrifugation (150,000 g, 30 min.,  $4^{\circ}$  C) and used as a source of PTK activity in the assays.

Determination of PTK activity by means of the filter paper assay with trichloroacetic acid (TCA):

The tyrosine phosphorylation of synthetic substrate was measured with a modified version of the method of Braun et al. [J. Biol. Chem. 259, 2051-2054 (1984)]. The PTK activity was measured at  $20^{\circ}$  C in a total volume of 64  $\mu$ l containing 50 mM Tris/HCl, pH 7.5, 20 mM Mg acetate, 5 mM NaF, 0.2 mM EDTA, 0.8 mM ethylenedioxy-bis(ethylenitrilo)tetraacetic acid (EGTA), 30  $\mu$ M  $\text{Na}_3\text{VO}_4$ , 1 mM dithiothreitol, 167  $\mu$ M PGT (equivalent to 5 mM tyrosine residues) and 3  $\mu$ g sample protein. The reaction was started by adding 50  $\mu$ M [ $^{32}$ P]ATP having a specific activity of 0.75 Ci/mmol.

After 12 min., the reaction was terminated by adding 25  $\mu$ l of a solution containing 17.5 mM ATP and 70 mM EDTA. After terminating the reaction, aliquots of the mixture were placed on Whatmann 3MM paper, precipitated with TCA and washed thoroughly with 10% TCA and 100 mM  $\text{PP}_i$ . The paper discs were washed in ethanol/ether (1/1) and then in ether and dried in air. The incorporation of the label was determined quantitatively by means of liquid scintillation counting. The tyrosine kinase activity was calculated by subtracting the background phosphorylation of endogenous proteins, measured as described above in the absence of PGT substrate. The PTK activity was expressed in pmol ATP/min/mg protein. The protein content was determined in accordance with Lowry et al. [J. Biol. Chem. 139, 265-275 (1951)].

Preparation of phosphorylated PGT standard:

A phosphorylated PGT standard was prepared by incubating 200  $\mu$ g of cytosol protein obtained from a breast carcinoma containing 1.6 mg PGT and 500  $\mu$ M ATP in tyrosine kinase buffer (see above) for 22 hours at 4° C in a volume of 1.2 ml. The phosphorylation was terminated by adding 25 mM EDTA/EGTA (final concentration). The mixture was divided into small aliquots and stored at -70° C until the instant of use as a standard.

A phosphorylation reaction with [ $\gamma$ - $^{32}\text{P}$ ]ATP was carried out in parallel under identical conditions in order to determine quantitatively the phosphate incorporated in accordance with the TCA filter paper determination (see above). The incorporation was calculated as 3.5 mmol/mol tyrosyl residues.

Determination of PTK activity according to the invention (dot-blot assay):

The PTK activity was determined in 30  $\mu$ l of a mixture which contained 50 mM Tris/HCl, pH 7.5, 20 mM Mg acetate, 5 mM NaF, 0.2 mM EDTA, 0.8 mM EGTA, 1.0 mM dithiothreitol, 30  $\mu$ M  $\text{Na}_2\text{VO}_4$ , 300  $\mu$ M ATP, 50  $\mu$ M PGT (equivalent to 1.8 mM Tyr residues) and 3  $\mu$ g sample protein. The reaction was started by adding ATP. After incubating for 1 hour at 37° C, the phosphorylation reaction was terminated by adding 5  $\mu$ l of a solution of 175 mM EDTA and 175 mM EGTA. The mixture was diluted with 140  $\mu$ l water, after which 25  $\mu$ l-

quantities of the mixture were placed on a PVDF membrane making use of a dot blot apparatus (Bio-Dot apparatus, Biorad, Richmond, CA, USA). The phosphotyrosine residues were then detected with the aid of the immunogold-silver staining procedure. Blocking of unoccupied membrane bonding sites, probing with primary antibody (1G2 antiphosphotyrosine, 2 µg/ml) and silver enhancement of the gold-labelled second antibody (goat antimouse IgG) were carried out in accordance with the instructions of the manufacturer of the respective reagents (Janssen, Belgium). The membrane was dried in air and the immunogold-silver signal was determined quantitatively by scanning the spots at 520 nm in a Beckman CDS 200 densitometer. The PTK activity was calculated from a phosphorylated PGT standard calibration curve. The activity was expressed in pmol ATP/min/mg protein.

#### RESULTS:

A phosphotyrosyl residue calibration curve was obtained by mixing unphosphorylated PGT and phosphorylated PGT standards in varying proportions. 5 µl quantities containing in total 5.7 µg (P)-PGT were placed on the PVDF membrane and these quantities correspond to those which were used in the PTK determination. Silver staining of the immunogold label and quantitative determination by means of densitometry yielded a linear response up to at least 20 pmol phosphotyrosine (Fig. 1). No background signal of unphosphorylated PGT was observed. The sensitivity of the method is such that a quantitative determination of less than 1.0 pmol phosphotyrosine is possible.

The calibration curves shown in Fig. 1 were used to determine quantitatively the PTK activity of the cytosol fraction of a breast carcinoma as a function of time and sample protein. Fig. 2 indicates that the reaction had a linear variation with time up to 2.5 hours. In control tests, the assays were carried out in the presence of EDTA/EGTA (25 mM each). Virtually no signal was obtained which indicated that the phosphorylation reaction is completely blocked by adding these reagents.

Variation in the amount of sample protein showed that the

reaction had a linear variation with enzyme activity up to approximately 5  $\mu\text{g}$  sample protein per assay (Fig. 3). With larger quantities of sample, the signal began to level off. In order to determine whether the signal originated specifically from the phosphorylation of added PGT or from the presence of endogenous proteins phosphorylated on tyrosine or from aspecific absorptions in the immunogold silver staining, parallel controls were carried out in the absence of PGT. A significant background staining became observable only with large quantities of sample protein (> 10  $\mu\text{g}$  per assay), and this indicates that the contribution of both endogenous protein phosphorylation and of aspecific absorptions is quantitatively negligible in the signal.

Optimal substrate concentrations were determined on the basis of kinetic studies on the enzyme originating from breast carcinoma. To determine the  $K_m$ , PGT calibration curves were constructed in another manner: only the quantity of phosphorylated PGT standard was varied without adjusting the total quantity of (P)-PGT with unphosphorylated PGT. The calibration lines obtained in this process were essentially the same as those shown in Fig. 1, and from this it is evident that the bonding properties of the membrane for the substrate is not of decisive influence in these tests. The enzyme showed normal Michaelis-Menten kinetics both for ATP and for PGT (Figs. 4 and 5), with  $K_m$  ATP =  $75 \pm 13 \mu\text{M}$  and  $K_m$  PGT =  $175 \pm 39 \mu\text{M}$  (expressed in the concentration of tyrosyl residues). In the assay, 300  $\mu\text{M}$  ATP and 1.8 mM Tyr (equivalent to 50  $\mu\text{M}$  PGT) were therefore chosen as optimum concentrations.

In the subsequent series of experiments, the conventional filter paper assay was compared with the new dot-blot assay according to the invention. Cytosol fractions were prepared from normal breast tissue ( $n = 2$ ), benign breast tumours ( $n = 3$ ) and malignant breast carcinomas ( $n = 5$ ) and investigated for PTK activity. The comparison of the two determinations is shown in Fig. 6. A linear correlation was obtained with a correlation coefficient of 0.98. The activities determined according to the method of the invention were approximately 4 times as high as in the filter paper assay. This difference appears to be due mainly to the difference in incubation temperature and only to a small

extent to differences in the substrate concentrations (results not shown). For practical reasons, the incubations with [ $^{32}$ P]ATP were carried at 20° C, while the incubation preceding the method according to the invention was carried out at 37° C. The lower detection limit of both assays was comparable. The sensitivity of the filter paper assay was, however, strongly dependent on the degree of background phosphorylation of endogenous protein (probably mainly on serine residues). As stated above, no background signal was observed in the determination according to the invention.

#### EXAMPLE II

##### Determination of the tyrosine phosphatase activity

200 µg of cytosol protein obtained from human granulocytes were incubated with 0.5 mg PGT and 0.5 mM ATP in tyrosine kinase buffer (see Example I) for 22 hours at 20° C in a volume of 1.2 ml. The phosphorylation was terminated by adding 110 µl 6 M TCA. After one hour at 4° C, the protein precipitate formed was centrifuged off (5 min., 12,000 x g). The pellet was washed a further three times with 0.6 M TCA. The last pellet was dissolved in 100 µl 1 N NaOH, after which the volume was made up to 2 ml with 50 mM Hepes, pH 7.0, containing 25 mM β-mercaptoethanol. A phosphorylation reaction with [ $^{32}$ P]ATP was carried out in parallel under identical conditions to determine the phosphate incorporated quantitatively in accordance with the TCA filter paper assay (see Example I). The incorporation was calculated at 0.8 mmol/mol tyrosyl residues.

The tyrosine phosphatase activity of a sample (for example, total cell extract of leukaemia cells) was determined in 30 µl of a mixture which contains 50 mM Hepes, pH 7.0, 25 mM β-mercaptoethanol and 15 µg phosphorylated PGT (equivalent to 20 pmol phosphotyrosyl residues). The reaction was started by adding that quantity of sample protein which is able to dephosphorylate not more than 3/4 of the available quantity of phosphotyrosyl residues in 30 min. at 37° C. After incubating for 30 min. at 37° C, the reaction was stopped by adding 5 µl of a solution of 0.25 mM

$\text{Na}_3\text{VO}_4$ . 5  $\mu\text{l}$  quantities of the mixture were transferred to a PVDF membrane and the amount of phosphotyrosine residues was quantified as described in the PTK determination according to Example I.

## CLAIMS

1. Method for determining the tyrosine-phosphorylating or phosphotyrosine-dephosphorylating activity of a material by bringing the material into contact with a polypeptide containing tyrosine or phosphotyrosine respectively and a phosphate source or phosphate acceptor respectively and then assaying the phosphorylated polypeptide, characterized in that the phosphorylated polypeptide is determined by using an antibody to polypeptide containing phosphotyrosine.

2. Method according to Claim 1, characterized in that the antibody is monospecific.

3. Method according to Claim 1 or 2, characterized in that the antibody is labelled.

4. Method according to Claim 1 or 2, characterized in that, to assay the phosphorylated polypeptide, a second, labelled antibody is also used.

5. Method according to Claim 3 or 4, characterized in that the labelled antibody is labelled with gold, whereby the signal of the gold-labelled antibody is optionally enhanced with silver.

6. Method according to Claim 1 or 2, characterized in that the polypeptide containing tyrosine or phosphotyrosine is labelled, preferably with an enzyme.

7. Method according to one of Claims 1-6, characterized in that the phosphorylating activity of one or more protein tyrosine kinases is determined.

8. Method according to one of Claims 1-7, characterized in that adenosine triphosphate or guanosine triphosphate is used as a phosphate source.

9. Method according to Claim 7 or 8, characterized in that the tyrosine-containing polypeptide is a synthetic polypeptide.

10. Method according to Claim 9, characterized in that the polypeptide also contains glutamic acid residues.

11. Method according to Claim 9 or 10, characterized in that the polypeptide has a random amino acid sequence.

12. Method according to one of Claims 1-6, characterized in that the dephosphorylating activity of one or more tyrosine

phosphatases is determined.

13. Kit for determining the tyrosine-phosphorylating and/or phosphotyrosine-dephosphorylating activity of a material, which contains at least one tyrosine-containing polypeptide and/or a phosphotyrosine-containing polypeptide, and an antibody to polypeptide containing phosphotyrosine.

14. Kit according to Claim 13, characterized in that the antibody is monospecific.

15. Kit according to Claim 13 or 14, characterized in that either the polypeptide or the antibody is provided with a labelling substance.

16. Kit according to Claim 13 or 14, characterized in that it also contains a labelled antibody against the antibody to polypeptide containing phosphotyrosine.

17. Kit according to one of Claims 13-16, characterized in that the polypeptide containing tyrosine or phosphotyrosine is a synthetic polypeptide.

18. Kit according to Claim 17, characterized in that the polypeptide also contains glutamic acid residues.

19. Kit according to Claim 17 or 18, characterized in that the polypeptide has a random amino acid sequence.

20. Kit according to one of Claims 11-19, characterized in that it also contains a carrier for immobilizing the polypeptide and/or the antibody.

21. Kit according to one of Claims 11-20, characterized in that it contains a tyrosine-containing polypeptide and also a phosphate source such as ATP.

22. Kit according to one of Claims 11-21, characterized in that it also contains a medium suitable for carrying out the determination and other constituents such as an inhibitor.

23. Kit according to one of Claims 11-22, characterized in that it also contains an instruction for carrying out the method according to one of Claims 1-12.



1/3

fig -1





fig -2



2/3

fig - 3







fig - 4




3/3



# INTERNATIONAL SEARCH REPORT

International Application No PCT/NL 90/00023

<b>I. CLASSIFICATION F SUBJECT MATTER</b> (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC <sup>5</sup> : G 01 N 33/68, G 01 N 33/573, C 12 P 21/00		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
IPC <sup>5</sup>	G 01 N, C 12 P	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT *</b>		
Category *	Citation of Document, ** with Indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
X	US, A, 4543439 (A.R. FRACKELTON et al.) 24 September 1985 see the whole document	1-3,7,8, 12-15,21,23
X	Biological Abstracts, vol. 88, no. 12, 1989, G. Rijksen et al.: "A nonradioactive dot-blot assay for protein tyrosine kinase activity", see page 317, abstract 129533, & Anal. Biochem. 182(1), 98-102, 1989	1-23
A	Journal of Immunological Methods, vol. 109, no. 2, 1988, Elsevier Science Publishers B.V.; (Amsterdam, NL), J.R. Glenney et al.: "Monoclonal antibodies to phosphotyrosine", pages 277-285 see the whole article	1-3,7,12- 15,23
-----		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
5th June 1990	0 2. 07. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	F.W. HECK 	

NL 9000023  
SA 35165

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4543439	24-09-85	None	